180 related articles for article (PubMed ID: 27861549)
1. A Histopathological Feature of EGFR-Mutated Lung Adenocarcinomas with Highly Malignant Potential - An Implication of Micropapillary Element.
Matsumura M; Okudela K; Kojima Y; Umeda S; Tateishi Y; Sekine A; Arai H; Woo T; Tajiri M; Ohashi K
PLoS One; 2016; 11(11):e0166795. PubMed ID: 27861549
[TBL] [Abstract][Full Text] [Related]
2. Specific expression of MUC21 in micropapillary elements of lung adenocarcinomas - Implications for the progression of EGFR-mutated lung adenocarcinomas.
Matsumura M; Okudela K; Nakashima Y; Mitsui H; Denda-Nagai K; Suzuki T; Arai H; Umeda S; Tateishi Y; Koike C; Kataoka T; Irimura T; Ohashi K
PLoS One; 2019; 14(4):e0215237. PubMed ID: 30973916
[TBL] [Abstract][Full Text] [Related]
3. Frequent DYRK2 gene amplification in micropapillary element of lung adenocarcinoma - an implication in progression in EGFR-mutated lung adenocarcinoma.
Koike C; Okudela K; Matsumura M; Mitsui H; Suzuki T; Arai H; Kataoka T; Ishikawa Y; Umeda S; Tateishi Y; Ohashi K
Histol Histopathol; 2021 Mar; 36(3):305-315. PubMed ID: 33368138
[TBL] [Abstract][Full Text] [Related]
4. Relevance of EGFR mutation with micropapillary pattern according to the novel IASLC/ATS/ERS lung adenocarcinoma classification and correlation with prognosis in Chinese patients.
Chao L; Yi-Sheng H; Yu C; Li-Xu Y; Xin-Lan L; Dong-Lan L; Jie C; Yi-Lon W; Hui LY
Lung Cancer; 2014 Nov; 86(2):164-9. PubMed ID: 25236981
[TBL] [Abstract][Full Text] [Related]
5. Correlation of survival and EGFR mutation with predominant histologic subtype according to the new lung adenocarcinoma classification in stage IB patients.
Sun Y; Yu X; Shi X; Hong W; Zhao J; Shi L
World J Surg Oncol; 2014 May; 12():148. PubMed ID: 24885205
[TBL] [Abstract][Full Text] [Related]
6. KRAS Mutation Is a Significant Prognostic Factor in Early-stage Lung Adenocarcinoma.
Kadota K; Sima CS; Arcila ME; Hedvat C; Kris MG; Jones DR; Adusumilli PS; Travis WD
Am J Surg Pathol; 2016 Dec; 40(12):1579-1590. PubMed ID: 27740967
[TBL] [Abstract][Full Text] [Related]
7. Overexpression of YAP1 in EGFR mutant lung adenocarcinoma prior to tyrosine kinase inhibitor therapy is associated with poor survival.
Hong SA; Jang SH; Oh MH; Kim SJ; Kang JH; Hong SH
Pathol Res Pract; 2018 Mar; 214(3):335-342. PubMed ID: 29487002
[TBL] [Abstract][Full Text] [Related]
8. Primary lung adenocarcinoma with morule-like components: a unique histologic hallmark of aggressive behavior and EGFR mutation.
Tsuta K; Kawago M; Yoshida A; Sekine S; Asamura H; Furuta K; Kushima R
Lung Cancer; 2014 Jul; 85(1):12-8. PubMed ID: 24768118
[TBL] [Abstract][Full Text] [Related]
9. Intratumoral Heterogeneity of ALK-Rearranged and ALK/EGFR Coaltered Lung Adenocarcinoma.
Cai W; Lin D; Wu C; Li X; Zhao C; Zheng L; Chuai S; Fei K; Zhou C; Hirsch FR
J Clin Oncol; 2015 Nov; 33(32):3701-9. PubMed ID: 26416997
[TBL] [Abstract][Full Text] [Related]
10. Features and prognostic impact of distant metastasis in patients with stage IV lung adenocarcinoma harboring EGFR mutations: importance of bone metastasis.
Fujimoto D; Ueda H; Shimizu R; Kato R; Otoshi T; Kawamura T; Tamai K; Shibata Y; Matsumoto T; Nagata K; Otsuka K; Nakagawa A; Otsuka K; Katakami N; Tomii K
Clin Exp Metastasis; 2014 Jun; 31(5):543-51. PubMed ID: 24682604
[TBL] [Abstract][Full Text] [Related]
11. Clonal History and Genetic Predictors of Transformation Into Small-Cell Carcinomas From Lung Adenocarcinomas.
Lee JK; Lee J; Kim S; Kim S; Youk J; Park S; An Y; Keam B; Kim DW; Heo DS; Kim YT; Kim JS; Kim SH; Lee JS; Lee SH; Park K; Ku JL; Jeon YK; Chung DH; Park PJ; Kim J; Kim TM; Ju YS
J Clin Oncol; 2017 Sep; 35(26):3065-3074. PubMed ID: 28498782
[TBL] [Abstract][Full Text] [Related]
12. Comparing the effects of afatinib with gefitinib or Erlotinib in patients with advanced-stage lung adenocarcinoma harboring non-classical epidermal growth factor receptor mutations.
Shen YC; Tseng GC; Tu CY; Chen WC; Liao WC; Chen WC; Li CH; Chen HJ; Hsia TC
Lung Cancer; 2017 Aug; 110():56-62. PubMed ID: 28676220
[TBL] [Abstract][Full Text] [Related]
13. Clinicopathologic characteristics and prognostic significance of EGFR and p53 mutations in surgically resected lung adenocarcinomas ≤2 cm in maximal dimension.
Lin MW; Wu CT; Shih JY; Chang YL; Yang PC
J Surg Oncol; 2014 Aug; 110(2):99-106. PubMed ID: 24788590
[TBL] [Abstract][Full Text] [Related]
14. High-grade lung adenocarcinomas with micropapillary and/or solid patterns: a review.
Morales-Oyarvide V; Mino-Kenudson M
Curr Opin Pulm Med; 2014 Jul; 20(4):317-23. PubMed ID: 24852329
[TBL] [Abstract][Full Text] [Related]
15. EGFR Mutation Impact on Definitive Concurrent Chemoradiation Therapy for Inoperable Stage III Adenocarcinoma.
Tanaka K; Hida T; Oya Y; Oguri T; Yoshida T; Shimizu J; Horio Y; Hata A; Kaji R; Fujita S; Sekido Y; Kodaira T; Kokubo M; Katakami N; Yatabe Y
J Thorac Oncol; 2015 Dec; 10(12):1720-5. PubMed ID: 26743855
[TBL] [Abstract][Full Text] [Related]
16. The nonsmokers' and smokers' pathways in lung adenocarcinoma: Histological progression and molecular bases.
Okudela K; Matsumura M; Arai H; Woo T
Cancer Sci; 2021 Sep; 112(9):3411-3418. PubMed ID: 34143937
[TBL] [Abstract][Full Text] [Related]
17. Heterogeneous components of lung adenocarcinomas confer distinct EGFR mutation and PD-L1 expression.
Cai Y; Wu H; Shi X; Dong Y; Chang X; Zhang L; Zhou L; Su D; Yang M
BMC Cancer; 2020 Feb; 20(1):148. PubMed ID: 32093629
[TBL] [Abstract][Full Text] [Related]
18. Epidermal growth factor receptor mutations are linked to skip N2 lymph node metastasis in resected non-small-cell lung cancer adenocarcinomas.
Guerrera F; Renaud S; Tabbó F; Voegeli' AC; Filosso PL; Legrain M; Boita M; Schaeffer M; Beau-Faller M; Ruffini E; Falcoz PE; Inghirami G; Oliaro A; Massard G
Eur J Cardiothorac Surg; 2017 Apr; 51(4):680-688. PubMed ID: 28329143
[TBL] [Abstract][Full Text] [Related]
19. Correlation of mutation status and survival with predominant histologic subtype according to the new IASLC/ATS/ERS lung adenocarcinoma classification in stage III (N2) patients.
Russell PA; Barnett SA; Walkiewicz M; Wainer Z; Conron M; Wright GM; Gooi J; Knight S; Wynne R; Liew D; John T
J Thorac Oncol; 2013 Apr; 8(4):461-8. PubMed ID: 23486266
[TBL] [Abstract][Full Text] [Related]
20. Prognostic value of epidermal growth factor receptor gene mutation in resected lung adenocarcinoma.
Deng C; Zhang Y; Ma Z; Fu F; Deng L; Li Y; Chen H
J Thorac Cardiovasc Surg; 2021 Sep; 162(3):664-674.e7. PubMed ID: 32747123
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
